Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer

Phase 2 Completed 50 enrolled Aiping Zhou

NaSingle-groupOpen-labelTreatment

Summary

This study aims to investigate the feasibility, safety and efficacy of triplet regimen of neoadjuvant chemotherapy in patients with locally advanced rectal cancer

Timeline

Start: 2016-02-06
Primary completion: 2019-03-01
Completion: 2020-04-01

Publications

Zhang W, Zhou H, Jiang J, Zhu Y, Zou S, Jiang L, Tang Y, Liang J, Sun Y, Jiang Z, Qu W, Li Y, Zhou A. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial. BMC Cancer. 2023 Jun 27;23(1):592. doi: 10.1186/s12885-023-11103-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	150 mg/m2	—
Subject	Leucovorin	Small molecule	—	—
Subject	Oxaliplatin	Small molecule	85 mg/m2	—
Subject	fluorouracil	Small molecule	2400 mg/m2	—

Indications

No indication recorded.